Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
T cell responses shape infant SIV reservoirs and postintervention control after AAV9-eCD4-Ig and latency reversal
Jairo A. Fonseca, Alexis C. King, Kaleaha S. Davis, Daniel O’Hagan, Adrian Khoei, Lucas Alves Britto Da Costa, Camryn Cockerham, Mackenzie Cottrell, Stephanie Ehnert, Jennifer S. Wood, Michael D. Alpert, Matthew R. Gardner, Jeffrey D. Lifson, Maud Mavigner, Mauricio A. Martins, Ann Chahroudi
Jairo A. Fonseca, Alexis C. King, Kaleaha S. Davis, Daniel O’Hagan, Adrian Khoei, Lucas Alves Britto Da Costa, Camryn Cockerham, Mackenzie Cottrell, Stephanie Ehnert, Jennifer S. Wood, Michael D. Alpert, Matthew R. Gardner, Jeffrey D. Lifson, Maud Mavigner, Mauricio A. Martins, Ann Chahroudi
View: Text | PDF
Research Article AIDS/HIV Immunology Infectious disease

T cell responses shape infant SIV reservoirs and postintervention control after AAV9-eCD4-Ig and latency reversal

  • Text
  • PDF
Abstract

Early antiretroviral therapy (ART) limits viral reservoir establishment in infants but also constrains virus-specific immunity required to clear reactivated cells. In the early ART context, we evaluated whether combining adeno-associated virus serotype 9–vectored (AAV9-vectored) eCD4-IgG1 with pharmacological latency reversal using the second mitochondria-derived activator of caspases (SMAC) mimetic AZD5582 could promote reservoir reduction and control in SIV-infected infant macaques. AAV9 delivery achieved sustained eCD4-IgG1 expression, and AZD5582 induced on-ART viremia, but the combination did not reduce intact SIV proviral DNA relative to controls. Partial postintervention control of viremia during analytical treatment interruption (ATI) occurred in 2 of 6 infants receiving AAV9-eCD4-IgG1 plus AZD5582 with restricted reservoir expansion during recrudescence at week 13. Intact reservoir size during ATI correlated inversely with on-ART viremia during AZD5582 treatment. Animals were classified as controllers or non-controllers. Controllers did not show increased eCD4-IgG1 expression nor increased on-ART viremia during AZD5582 treatment but harbored less pre-ART intact SIV DNA in PBMCs than non-controllers. Controllers also exhibited higher frequencies and greater polyfunctionality of virus-specific CD8+ T cells prior to ATI. These findings suggest immune control of reservoir size and post-ART viral dynamics in early-treated infants and that AAV9-eCD4-IgG1 plus AZD5582 increases the likelihood of post-ART viral control.

Authors

Jairo A. Fonseca, Alexis C. King, Kaleaha S. Davis, Daniel O’Hagan, Adrian Khoei, Lucas Alves Britto Da Costa, Camryn Cockerham, Mackenzie Cottrell, Stephanie Ehnert, Jennifer S. Wood, Michael D. Alpert, Matthew R. Gardner, Jeffrey D. Lifson, Maud Mavigner, Mauricio A. Martins, Ann Chahroudi

×

Figure 1

Study design and intervention regimen.

Options: View larger image (or click on image) Download as PowerPoint
Study design and intervention regimen.
Twenty infant rhesus macaques wer...
Twenty infant rhesus macaques were orally challenged with SIVmac251 at 4 weeks of age and randomly assigned to intervention or control groups (n = 10 per group), and then allocated to a dose optimization cohort (n = 8; 4 per group) or an ATI cohort (n = 12; 6 per group). All time points are weeks after infection. All animals initiated ART at week 3 (gray shading); plasma viral load (PVL) was monitored weekly through week 6 and biweekly thereafter. Intervention animals received AAV9 encoding eCD4-IgG1 (2.5 × 1012 genome copies kg–1) at week 3, followed by 6 weekly doses of the latency reversal agent AZD5582 beginning at week 40; control animals received ART alone. Dose optimization animals were euthanized during or after AZD5582 administration, with time-matched control animals euthanized at corresponding time points. In the ATI cohort, ART was interrupted 4 weeks after completion of the AZD5582 regimen (tan shading); animals were euthanized a mean of 18 weeks after ATI, with paired control animals euthanized at matched time points. Created with BioRender.com.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts